Highlights Glaukos Corporation

Equities

GKOS

US3773221029

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
99.48 ^USD	-0.63%		+3.09%	+25.15%

Apr. 11	Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating	MT
Apr. 11	Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Rise Wednesday Afternoon	Apr. 03	MT
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services	Apr. 03	MT
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)	Apr. 03	CI
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase	Feb. 21	MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Revenue $82.4M, vs. Street Est of $78.5M	Feb. 21	MT
Glaukos Corporation Reaffirms Financial Guidance for 2024	Feb. 21	CI
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Glaukos Preliminary Q4 Net Sales Top Estimates; 2024 Revenue Outlook Reaffirmed; Shares Rise	Jan. 09	MT
Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024	Jan. 09	CI
Glaukos Shares Jump After US FDA Approves New Drug Application for iDose TR	Dec. 14	MT
Glaukos Says FDA Approves New Drug Application for iDose TR	Dec. 14	MT
Glaukos Corporation Re-Affirms Revenue Guidance for the Year 2023 and 2024	Dec. 14	CI
Glaukos Corporation Announces FDA Approval of iDose® TR (travoprost intracameral implant)	Dec. 14	CI
Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Revenue $78M, vs. Street Est of $75.3M	Nov. 01	MT
Glaukos Corporation Revises Consolidated Revenue Guidance for the Year 2023	Nov. 01	CI
Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Revenue $80.4M, vs. Street Est of $74.7M	23-08-02	MT
Glaukos Corporation Revises Sales Guidance for the Year 2023	23-08-02	CI
Glaukos Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Glaukos Signs Collaboration, Marketing Agreement With Radius XR	23-07-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Glaukos Corporation

Equities

GKOS

US3773221029

Highlights

Filters